Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: Effect against amyloid-β-induced neurotoxicity

ACS Chemical Neuroscience

Volumn 4, Issue 4, 2013, Pages 547-565

  Silva, Daniel ^a,b   Chioua, Mourad ^b   Samadi, Abdelouahid ^b   Agostinho, Paula ^c,d   Garção, Pedro ^c,d   Lajarín Cuesta, Rocío ^e   De Los Ríos, Cristobal ^e   Iriepa, Isabel ^f   Moraleda, Ignacio ^f   Gonzalez Lafuente, Laura ^e   Mendes, Eduarda ^a   Pérez, Concepción ^g   Rodríguez Franco, María Isabel ^g   Marco Contelles, José ^b   Carmo Carreiras, M ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f UNIVERSITY OF ALCALÁ   (Spain)

^g INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

A peptide; AChE BuChE inhibitors; Alzheimer's disease; Ca2+ dyshomeostasis; neuroprotection; Pyridonepezils; quinolinodonepezils

Indexed keywords

1 (4 HYDROXYPHENYL)ETHANONE; 1 BENZYLPIPERIDINE 4 CARBALDEHYDE; 2 (1 BENZYLPIPERIDIN 4 YL)ETHANAMINE; 2 (4 HYDROXYBENZYLIDENE)MALONONITRILE; 4 (1 BENZYLPIPERIDIN 4 YL)BUTAN 1 AMINE; 4 (4 AZIDOBUTYL) 1 BENZYLPIPERIDINE; 4 AMINO 1 BENZYLPIPERIDINE; 6 ((1 BENZYLPIPERIDIN 4 YLIDENE)METHYL) 2 ETHOXY 7 METHYL 4 PHENYL 1,8 NAPHTHYRIDINE 3 CARBONITRILE; 6 ((N BENZYLPIPERIDIN 4YL)ALKYLAMINO) 5 CYANO 2 METHYL 4 PHENYLNICOTINATE; 6 (4 (1 BENZYLPIPERIDIN 4 YL)BUTYLAMINO) 5 CYANO 2 METHYL 4 PHENYL NICOTINATE; 7 (2 (1 BENZYLPIPERIDIN 4 YL)ETHYL) 2 ETHOXY 4 PHENYL 1,8 NAPHTHYRIDINE 3 CARBONITRILE; AMYLOID BETA PROTEIN; CALCIUM CHANNEL; CHOLINESTERASE INHIBITOR; DONEPEZIL; ETHYL 6 ((1 BENZYLPIPERIDIN 4 YL)METHYLAMINO) 5 CYANO 2 METHYL 4 PHENYLNICOTINATE; ETHYL 6 (1 BENZYLPIPERIDIN 4 YLAMINO) 5 CYANO 2 METHYL 4 PHENYLNICOTINATE; ETHYL 6 (2 (1 BENZYLPIPERIDIN 4 YL)ETHYLAMINO) 5 CYANO 2 METHYL 4 PHENYLNICOTINATE; ETHYL 6 (3 (1 BENZYLPIPERIDIN 4 YL)PROPYLAMINO) 5 CYANO 2 METHYL 4 PHENYLNICOTINATE; ETHYL 6 (4 (1 BENZYLPIPERIDIN 4 YL)BUTYLAMINO) 5 CYANO 2 METHYL 4 PHENYLNICOTINATE; ETHYL 6 AMINO 2 ((BENZYLOXY)METHYL) 5 CYANO 4 (4 FLUOROPHENYL) 4H PYRAN 3 CARBOXYLATE; ETHYL 6 AMINO 5 CYANO 2 METHYL 4 ARYLNICOTINATE; ETHYL 6 CHLORO 5 CYANO 2 METHYL 4 PHENYLNICOTINATE; PHENOXYALKOXYBENZYLIDENEMALONONITRILE; PHENOXYALKYLAMINO 4 PHENYLNICOTINATE; PYRAZOLO[3,4 ]QUINOLINE; PYRAZOLO[3,4 B]QUINOLINE; PYRIDONEPEZIL; QUINOLINODONEPEZIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; DEPOLARIZATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN CONFORMATION; UPREGULATION;

AMYLOID BETA-PEPTIDES; BUTYRYLCHOLINESTERASE; CELL LINE, TUMOR; CELL SURVIVAL; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, MOLECULAR; PEPTIDE FRAGMENTS;

EID: 84876529529     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn300178k     Document Type: Article

References (72)

1. Bertram, L. and Tanzi, R. E. (2008) Thirty years of Alzheimer̀s disease genetics: the implications of systematic meta-analyses Nat. Rev. Neurosci. 9, 768-778
2. Shah, R. S., Lee, H.-G., Xiongwei, Z., Perry, G., Smith, M. A., and Castellani, R. J. (2008) Current approaches in the treatment of Alzheimer's disease Biomed. Pharmacother. 62, 199-207
3. Wenk, G. L. (2003) Neuropathologic changes in Alzheimer̀s disease J. Clin. Psychiatry 64, 7-10
4. Terry, A. V., Jr. and Buccafusco, J. J. (2003) The Cholinergic hypothesis of age and Alzheimer̀s disease-related cognitive deficits: Recent challenges and their implications for novel drug development J. Pharmacol. Exp. Ther. 306, 821-827
5. Francis, P. T., Palmer, A. M, Snape, M., and Wilcock, G. K. (1999) The Cholinergic hypothesis of Alzheimer̀s disease: a review of progress J. Neurol. Neurosurg. Psychiatry 66, 137-147
6. Benzi, G. and Moretti, A. (1998) Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer̀s disease? Eur. J. Pharmacol. 346, 1-13
7. Inestrosa, N. C, Alvarez, A., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C., and Garrido, J. (1996) Acetylcholinesterase acceleratyes assembly of amyloid-beta-peptides into Alzheimer̀s fibrils: possible role of the peripheral site of the enzyme Neuron 16, 881-91
8. Reyes, A. E., Perez, D. R., Alvarez, A., Garrido, J., Gentry, M. K., Doctor, B. P., and Inestrosa, N. C. (1997) A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme Biochem. Biophys. Res. Commun. 232, 652-655
9. Inestrosa, N. C., Alvarez, A., Godoy, J., Reyes, A., and De Ferrari, G. V. (2000) Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicitity Acta Neurol. Scand. Suppl. 102, 53-56
10. Mori, F., Lai, C. C., Fusi, F., and Giacobini, E. (1995) Cholinesterase inhibitors increase secretion of APPs in rat brain cortex NeuroReport 7, 633-636
11. Giacobini, E. (2003) Cholinesterases: New roles in brain function and in Alzheimeŕs disease Neurochem. Res. 28, 515-522
12. Francis, P. T., Nordberg, A., and Arnold, S. E. (2005) A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer̀s disease? Trends Pharmacol. Sci. 26, 104-111
13. Castro, A. and Martinez, A. (2001) Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer̀s disease Mini-Rev. Med. Chem. 1, 267-272
14. Pang, Y. P., Quiram, P., Jelaçic, T., Hong, F., and Brimijoin, S. (1996) Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease J. Biol. Chem. 271, 23646-23649
15. Carlier, P. R., Han, Y. F., Chow, E. S., Li, C. P., Lieu, T. X., Wong, H. S., and Pang, Y. P. (1999) Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis Bioorg. Med. Chem. 7, 351-357
16. Mary, A., Renko, D. Z., Guillou, C., and Thal, C. (1998) Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series Bioorg. Med. Chem. 6, 1835-1850
17. Bolognesi, M. L., Andrisano, V., Bartolini, M., Banzi, R., and Melchiorre, C. (2005) Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-β aggregation J. Med. Chem. 48, 24-27
18. Davis, K. L. and Powchick, P. (1995) Tacrine Lancet 345, 625-630
19. Spencer, C. M. and Noble, S. (1998) Rivastigmine. A review of its use in Alzheimer̀s disease Drugs Aging 13, 391-400
20. Barner, E. L. and Gray, S. L. (1998) Donepezil use in Alzheimer disease Ann. Pharmacother. 32, 70-77
21. Sramek, J. J., Frackiewicz, E. J., and Cutler, N. R. (2000) Review of the acetylcholinesterase inhibitor galanthamine Expert Opin. Invest. Drugs 9, 2393-2402
22. Li, W., Mak, M., Jiang, H., Wang, Q., Pang, Y., Chen, K., and Han, Y. (2009) Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets Neurotherapeutics 6, 187-201
23. Han, Y. F., Li, C. P.-L., Chow, E., Wang, H., Pang, Y. P., and Carlier, P. R. (1999) Dual-site binding of bivalent 4-aminopyridine- and 4-aminoquinoline-based AChE inhibitors: contribution of the hydrophobic alkylene tether to monomer and dimer affinities Bioorg. Med. Chem. 7, 2569-2575
24. Camps, P., Formosa, X., Galdeano, C., Gómez, T., Muñoz-Torrero, D., Scarpellini, M., Viayna, E., Badia, A., Clos, M. V., Camins, A., Pallás, M., Bartolini, M., Mancini, F., Andrisano, V., Estelrich, J., Lizondo, M., Bidon-Chanal, A., and Luque, F. J. (2008) Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation J. Med. Chem. 51, 3588-3598
25. Rodríguez-Franco, M. I., Fernández-Bachiller, M. I., Pérez, C., Hernández-Ledesma, B., and Bartolomé, B. (2006) Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties J. Med. Chem. 49, 459-462
26. Fang, L., Kraus, B., Lehmann, J., Heilmann, J., Zhang, Y., and Deckera, M. (2008) Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates Bioorg. Med. Chem. Lett. 18, 2905-2909
27. Sheng, R., Xu, Y., Hu, C., Zhang, J., Lin, X., Li, J., Yang, B., He, Q., and Hu, Y. (2009) Design, synthesis and AChE inhibitory activity of indanone and aurone derivatives Eur. J. Med. Chem. 44, 7-17
28. Piazzi, L., Cavalli, A., Colizzi, F., Belluti, F., Bartolini, M., Mancini, F., Recanatini, M., Andrisano, V., and Rampa, A. (2008) Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds Bioorg. Med. Chem. Lett. 18, 423-426
29. Mattson, M. P. and S. L. Chan, S. L. (2001) Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits J. Mol. Neurosci. 17, 205-224
30. Hölscher, C. (1998) Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis Neurobiol. Dis. 5, 129-141
31. Ripová, D., Platilová, V., Struneká, A., Jirák, R., and Höschl, C. (2000) Cytosolic calcium alterations in platelets of patients with early stages of Alzheimer̀s disease Neurobiol. Aging 5, 729-734
32. Demuro, A., Parker, I., and Stutzmann, G. E. (2010) Calcium signaling and amyloid toxicity in Alzheimer disease J. Biol. Chem. 285, 112463-12468
33. Bezprozvanny, I. and Mattson, M. P. (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease Trends Neurosci. 31, 454-463
34. Mattson, M. P. (2007) Calcium and neurodegeneration Aging Cell 6, 337-350
35. 2+ dyshomeostasis Curr. Med. Chem. 18, 552-576
36. León, R., García, A. G., and Marco-Contelles, J. (2013) Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's Disease Med. Res. Rev. 33, 139-189
37. Alonso, D., Dorronsoro, I., Rubio, L., Muñoz, P., García-Palomero, E., del Monte, M., Bidon-Chanal, A., Orozco, M., Luque, F. J., Castro, A., Medina, M., and Martínez, A. (2005) Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE Bioorg. Med. Chem. 13, 6588-6597
38. Samadi, A., Marco-Contelles, J., Soriano, E., álvarez- Pérez, M., Chioua, M., Romero, A., González-Lafuente, L., Gandía, L., Roda, J. M., López, M. G., Villarroya, M., García, A. G., and de los Ríos, C. (2010) Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles Bioorg. Med. Chem. 18, 5861-5872
39. Scipione, L., De Vita, D., Musella, A., Flammini, L., Bertoni, S., and Barocelli, E. (2008) 4-Aminopyridine derivatives with anticholinesterase and antiamnesic activity Bioorg. Med. Chem. Lett. 18, 309-312
40. Elkasaby, M. A. and F. Elshahed, F. (1981) Synthesis and reactions of 4-aryl-5-carbethoxy-3-cyano-6-methyl-2(H)-pyridones Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 20B, 428-431
41. Contreras, J. M., Rival, Y. M., Chayer, S., Bourguignon, J. J., and Wermuth, C. G. (1999) Aminopyridazines as acetylcholinesterase inhibitors J. Med. Chem. 42, 730-741
42. Samadi, A., Chioua, M., Bolea, I., de los Ríos, C., Iriepa, I., Moraleda, I., Bastida, A., Esteban, G., Unzeta, M., Gálvez, E., and Marco-Contelles, J. (2011) Synthesis, biological assessment and molecular modeling of new, multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment oif Alzheimer̀s disease Eur. J. Med. Chem. 46, 4665-4668
43. Bolea, I., Juárez, J., de los Ríos, C., Chioua, M., Pouplana, R., Luque, F. J., Unzeta, M., Marco-Contelles, J., and Samadi, A. (2011) Synthesis, biological evaluation, and molecular modeling of donepezil and N -[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]- N -methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease J. Med. Chem. 54, 8251-8270
44. Marco-Contelles, J., Pérez-Mayoral, M. E., Samadi, A., Carreiras, M. C., and Soriano, E. (2009) Recent Advances in the Friedländer reaction Chem. Rev. 109, 2652-2671
45. Marco, J. L. and Carreiras, M. C. (2010) The Friedländer Reaction, LAP Lambert Academic Publishing AG & Co. KG, Saarbrücken, Germany.
46. Fernandez-Mato, A., Blanco, G., Quintela, J. M., and Peinador, C. (2008) Synthesis of new bis(2.[1,8]naphthyridinyl) bridging ligands with multidentate binding sites Tetrahedron 64, 3446-3456
47. Nagarajan, S. and Das, T. M. (2009) Facile one-pot synthesis of sugar-quinoline derivatives Carbohydr. Res. 344, 1028-1031
48. Dormer, P. G., Eng, K. K., Farr, R. N., Humphrey, G. R., McWilliams, J. C., Reider, P. J., Sager, J. W., and Volante, R. P. (2003) Highly regiosselective Friedländer annulations with unmodified ketones employing novel amine catalysts: Syntheses of 2-substituted quinolines, 1,8-naphthyridines, and related heterocycles J. Org. Chem. 68, 467-477
49. Silva, D., Chioua, M., Samadi, A., Carreiras, M. C., Jimeno, M.-L., Mendes, M. E., de los Ríos, C., Romero, A., Villarroya, M., López, M. G., and Marco-Contelles, J. (2011) Synthesis and pharmacological assessment of diversely substituted pyrazolo[3,4- b ]quinoline, and benzo[ b ]pyrazolo[4,3- g ][1,8]naphthyridine derivatives Eur. J. Med. Chem. 46, 4676-4681
50. Ellman, G. L., Courtney, K. D., Andres, V., Jr., and Feather-Stone, R. M. (1961) A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 7, 88-95
51. Greig, N. H., Utsuki, T., Ingram, D., Wang, K. Y., Pepeu, G., Scali, C., Yu, Q. S., Mamczarz, J., Holloway, H. W., Giordano, T., Chen, D., Furukawa, K., Sambamurti, K., Brossi, A., and Lahiri, D. K. (2005) Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent Proc. Natl. Acad. Sci. U.S.A. 102, 17213-17218
52. Chan, S. L., Shirachi, D. Y., Bhargava, H. N., Gardner, E., and Trevor, A. J. (1972) Purification and properties of multiple forms of brain acetylcholinesterase (EC 3.1.1.7) J. Neurochem. 19, 2747-58
53. Ott, P., Lustig, A., Brodbeck, U., and Rosenbusch, J. P. (1982) Acetylcholinesterase from human erythrocytes membranes: dimers as functional units FEBS Lett. 138, 187-189
54. Rosenberry, T. L., Mallender, W. D., Thomas, P. J., and Szegletes, T. (1999) A steric blockade model for inhibition of acetylcholinesterase by peripheral site ligands and substrate Chem.-Biol. Interact. 119-120, 85-97
55. Lopes, J. P., Oliveira, C. R., and Agostinho, P. (2009) Cdk5 acts as a mediator of neuronal cell cycle re-entry triggered by amyloid-beta and prion peptides Cell Cycle 8, 97-104
56. Melo, J. B., Agostinho, P., and Oliveira, C. R. (2003) Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide Neurosci. Res. 45, 117-27
57. Thullbery, M. D., Cox, H. D., T. Schule, T., Thompson, C. M., and George, K. M. (2005) Differential localization of acetylcholinesterase in neuronal and non-neuronal cells J. Cell Biochem. 96, 599-610
58. 2+ signals and neurotransmitter release Mol. Pharmacol. 64, 1217-1226
59. Solntseva, E. I., Bukanova, J. V., Marchenko, E., and Skrebitsky, V. G. (2007) Donepezil is a strong antagonist of voltage-gated calcium and potassium channels in molluscan neurons Comp. Biochem. Physiol., Part C: Toxicol. Pharmacol. 144, 319-326
60. Trott, O. and Olson, A. J. (2010) AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading J. Comput. Chem. 31, 455-461
61. Bartolini, M., Pistolozzi, M., Andrisano, V., Egea, J., López, M. G., Iriepa, I., Moraleda, I., Gálvez, E., Marco-Contelles, J., and Samadi, A. (2011) Chemical and pharmacological studies on enantiomerically pure p-methoxytacripyrines, promising multi-target-directed ligands for the treatment of Alzheimer's disease ChemMedChem 6, 1990-1997
62. Martins, C., Carreiras, M. C., Leon, R., de los Rios, C., Bartolini, M., Andrisano, V., Iriepa, I., Moraleda, I., Galvez, E., Garcia, M., Egea, J., Samadi, A., Chioua, M., and Marco-Contelles, J. (2011) Synthesis and biological assessment of diversely substituted furo[2,3-b]quinolin-4-amine and pyrrolo[2,3-b]quinolin-4-amine derivatives, as novel tacrine analogues Eur. J. Med. Chem. 46, 6119-6130
63. Samadi, A., de los Rios, C., Bolea, I., Chioua, M., Iriepa, I., Moraleda, I., Bartolini, M., Andrisano, V., Galvez, E., Valderas, C., Unzeta, M., and Marco-Contelles, J. (2012) Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: Synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine Eur. J. Med. Chem. 52, 251-262
64. Maalej, E., Chabchoub, F., Oset-Gasque, M. J., Esquivias-Pérez, M., González, M. P., Monjas, L., Pérez, C., de los Ríos, C., Rodríguez-Franco, I., Iriepa, I., Moraleda, I., Chioua, M., Romero, A., Marco-Contelles, J., and Samadi, A. (2012) Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8] chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease Eur. J. Med. Chem. 54, 750-763
65. Wallace, A. C., Laskowski, R. A., and Thornton, J. M. (1996) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions Protein Eng. 8, 127-134
66. Arnold, K., Bordoli, L., Kopp, J., and Schwedge, T. (2006) The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling Bioinformatics 22, 195-201
67. Kiefer, F., Arnold, K., Künzli, M., Bordoli, L., and Schwede, T. (2009) The SWISS-MODEL Repository and associated resources Nucleic Acids Res. 37, D387-D392
68. Peitsch, M. C. (1995) Protein modeling by E-mail Bio/Technology 13, 658-660
69. Eichler, J., Anselment, A., Sussman, J. L., Massoulié, J., and Silman, J. (1994) Differential effects of ″peripheral″ site ligands on Torpedo and chicken acetylcholinesterase Mol. Pharmacol. 45, 335-40
70. Resende, R., Ferreiro, E., Pereira, C., and Oliveira, C. R. (2008) Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: Involvement of endoplasmic reticulum calcium release in oligomer-induced cell death Neuroscience 155, 725-737
71. Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., and Karplus, M. (1983) Charmm, a program for macromolecular energy, minimization, and dynamics calculations J. Comput. Chem. 4, 187-217
72. Morreale, A., Maseras, F., Iriepa, I., and Gálvez, E. (2002) Ligand-receptor interaction at the neural nicotinic acetylcholine binding site: A theoretical model J. Mol. Graphics Modell. 21, 111-118